Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0792
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2621
    -0.0001 (-0.01%)
     
  • USD/JPY

    151.2870
    -0.0850 (-0.06%)
     
  • Bitcoin USD

    70,146.98
    -249.23 (-0.35%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Mylan climbs on talk of sale

The maker of generic and branded drugs for the nervous system broke out Wed. as rumors circulated on Twitter that Mylan (MYL) might be for sale, possibly to Teva Pharma (TEVA), and as it announced 3 drug launches. Analysts were divided about the logic of Teva buying Mylan, a competitor in generic drugs. Meanwhile, Mylan launched a pain medication in the U.S., a generic version of a drug used to treat opioid dependence, and a generic of Antabuse, used to treat alcoholism. Mylan shares rose 6.7% to 59. Teva rose 2.5% to 57.61.

Advertisement